References
- Kumar R, Sanawar R, Li X, Li F. Structure, biochemistry, and biology of pak kinases. Gene 2017;605:20–31.
- Radu M, Semenova G, Kosoff R, Chernoff J. Pak signalling during the development and progression of cancer. Nat Rev Cancer 2014;14:13–25.
- Yao D, Pan D, Zhen Y, et al. Ferulin c triggers potent pak1 and p21-mediated anti-tumor effects in breast cancer by inhibiting tubulin polymerization in vitro and in vivo. Pharmacol Res 2020;152:104605.
- Zhang ZL, Liu GC, Peng L, et al. Effect of pak1 gene silencing on proliferation and apoptosis in hepatocellular carcinoma cell lines mhcc97-h and hepg2 and cells in xenograft tumor. Gene Ther 2018;25:284–96.
- Cao F, Yin LX. Pak1 promotes proliferation, migration and invasion of hepatocellular carcinoma by facilitating emt via directly up-regulating snail. Genomics 2020;112:694–702.
- Chen L, Bi S, Hou J, et al. Targeting p21-activated kinase 1 inhibits growth and metastasis via Raf1/MEK1/ERK signaling in esophageal squamous cell carcinoma cells. Cell Commun Signal 2019;17:31
- Shrestha Y, Schafer EJ, Boehm JS, et al. Pak1 is a breast cancer oncogene that coordinately activates mapk and met signaling. Oncogene 2012;31:3397–408.
- Yang Z, Wang H, Xia L, et al. Overexpression of pak1 correlates with aberrant expression of emt markers and poor prognosis in non-small cell lung cancer. J Cancer 2017;8:1484–91.
- Qu Y, Lin Z, Qi Y, et al. Pak1 expression determines poor prognosis and immune evasion in metastatic renal cell carcinoma patients. Urol Oncol 2019;38(4):293–304.
- Ong CC, Gierke S, Pitt C, et al. Small molecule inhibition of group i p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Res 2015;17:(59
- Abdel-Magid AF. Pak1: A therapeutic target for cancer treatment. ACS Med Chem Lett 2013;4:431–2.
- Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127–32.
- Murray BW, Guo C, Piraino J, et al. Small-molecule p21-activated kinase inhibitor pf-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U.S.A 2010;107:9446–51.
- Licciulli S, Maksimoska J, Zhou C, et al. Frax597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (nf2)-associated schwannomas. J Biol Chem 2013;288:29105–14.
- Karpov AS, Amiri P, Bellamacina C, et al. Optimization of a dibenzodiazepine hit to a potent and selective allosteric pak1 inhibitor. ACS Med Chem Lett 2015;6:776–81.
- Deacon SW, Beeser A, Fukui JA, et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 2008;15:322–31.
- Yeh ES, Means AR. PIN1, the cell cycle and cancer. Nat Rev Cancer 2007;7:381–8.
- Tateishi K, Omata M, Tanaka K, Chiba T. The NEDD8 system is essential for cell cycle progression and morphogenetic pathway in mice. J Cell Biol 2001;155:571–9.
- Zhang J, Zou L, Tang P, et al. Design, synthesis and biological evaluation of 1H-pyrazolo [3,4-d]pyrimidine derivatives as PAK1 inhibitors that trigger apoptosis, ER stress and anti-migration effect in MDA-MB-231 cells. Eur J Med Chem 2020;194:112220
- Yao D, Wang J, Wang G, et al. Design, synthesis and biological evaluation of coumarin derivatives as novel acetylcholinesterase inhibitors that attenuate h2o2-induced apoptosis in sh-sy5y cells. Bioorg Chem 2016;68:112–23.
- Crawford JJ, Lee W, Aliagas I, et al. Structure-guided design of group i selective p21-activated kinase inhibitors. J Med Chem 2015;58:5121–36.
- Case DA, Cheatham TE, Darden T, et al. The amber biomolecular simulation programs. J Comput Chem 2005;26:1668–88.
- Martinez Molina D, Jafari R, Ignatushchenko M, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 2013;341:84–7.